Last reviewed · How we verify
Dolisina — Competitive Intelligence Brief
phase 2
Pleiotropic ABC efflux transporter of multiple drugs
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Dolisina (DIETHAZINE). Dolisina is thought to work by interacting with a specific target in the body to produce a therapeutic effect.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dolisina TARGET | DIETHAZINE | phase 2 | Pleiotropic ABC efflux transporter of multiple drugs | |||
| Nozinan | LEVOMEPROMAZINE | Immunex | marketed | levomepromazine | Histamine H1 receptor, Pleiotropic ABC efflux transporter of multiple drugs | 1982-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Dolisina — Competitive Intelligence Brief. https://druglandscape.com/ci/diethazine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing